PGS Sample Set (PSS): PSS009633

Sample #1

Phenotype None
Sample Ancestry African American or Afro-Caribbean

Sample Numbers

Total number
10,875 individuals
Detailed numbers
5,505 cases (50.62%)
5,370 controls
100.0% Male samples
Number of Cohort(s) 4
Sample distribution
Sample gender distribution

Cohort(s)

Cohort Short Name Cohort Full Name Previous/other/additional names (e.g. sub-cohorts)
BPC3 The National Cancer Institute Breast and Prostate Cancer Cohort Consortium
CGEMS National Cancer Institute Cancer Genetic Markers of Susceptibility
Ghana Ghana
PEGASUS Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

Additional information

GENEVA, ICPCG, ONCO

Sample #2

Phenotype None
Sample Ancestry Asian unspecified

Sample Numbers

Total number
3,057 individuals
Detailed numbers
1,574 cases (51.49%)
1,483 controls
100.0% Male samples
Number of Cohort(s) 4
Sample distribution
Sample gender distribution

Cohort(s)

Cohort Short Name Cohort Full Name Previous/other/additional names (e.g. sub-cohorts)
BPC3 The National Cancer Institute Breast and Prostate Cancer Cohort Consortium
CGEMS National Cancer Institute Cancer Genetic Markers of Susceptibility
Ghana Ghana
PEGASUS Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

Additional information

GENEVA, ICPCG, ONCO

Sample #3

Phenotype None
Sample Ancestry European

Sample Numbers

Total number
91,623 individuals
Detailed numbers
54,564 cases (59.55%)
37,059 controls
100.0% Male samples
Number of Cohort(s) 4
Sample distribution
Sample gender distribution

Cohort(s)

Cohort Short Name Cohort Full Name Previous/other/additional names (e.g. sub-cohorts)
BPC3 The National Cancer Institute Breast and Prostate Cancer Cohort Consortium
CGEMS National Cancer Institute Cancer Genetic Markers of Susceptibility
Ghana Ghana
PEGASUS Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

Additional information

GENEVA, ICPCG, ONCO

Sample #4

Phenotype None
Sample Ancestry Sub-Saharan African (Ghanaian)

Sample Numbers

Total number
913 individuals
Detailed numbers
461 cases (50.49%)
452 controls
100.0% Male samples
Number of Cohort(s) 4
Sample distribution
Sample gender distribution

Cohort(s)

Cohort Short Name Cohort Full Name Previous/other/additional names (e.g. sub-cohorts)
BPC3 The National Cancer Institute Breast and Prostate Cancer Cohort Consortium
CGEMS National Cancer Institute Cancer Genetic Markers of Susceptibility
Ghana Ghana
PEGASUS Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

Additional information

GENEVA, ICPCG, ONCO

Sample #5

Phenotype None
Sample Ancestry Hispanic or Latin American

Sample Numbers

Total number
4,238 individuals
Detailed numbers
2,170 cases (51.2%)
2,068 controls
100.0% Male samples
Number of Cohort(s) 4
Sample distribution
Sample gender distribution

Cohort(s)

Cohort Short Name Cohort Full Name Previous/other/additional names (e.g. sub-cohorts)
BPC3 The National Cancer Institute Breast and Prostate Cancer Cohort Consortium
CGEMS National Cancer Institute Cancer Genetic Markers of Susceptibility
Ghana Ghana
PEGASUS Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

Additional information

GENEVA, ICPCG, ONCO